(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of 9.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Editas Medicine's revenue in 2024 is $78,123,000.On average, 8 Wall Street analysts forecast EDIT's revenue for 2024 to be $3,277,871,900, with the lowest EDIT revenue forecast at $2,046,982,527, and the highest EDIT revenue forecast at $5,317,900,250. On average, 7 Wall Street analysts forecast EDIT's revenue for 2025 to be $2,141,641,151, with the lowest EDIT revenue forecast at $1,636,277,000, and the highest EDIT revenue forecast at $2,577,136,275.
In 2026, EDIT is forecast to generate $11,057,632,711 in revenue, with the lowest revenue forecast at $6,935,932,761 and the highest revenue forecast at $19,801,406,116.